CK Life Sciences' Sequencio to Present Cancer Vaccine Data at SITC 2026, Advancing PINT Framework

Sequencio Therapeutics will present preclinical data at SITC 2026 showing its TROP2 and PD-L1/PRAME cancer vaccines generate targeted immune responses and inhibit tumor growth, supporting the PINT translational framework and potential human trials.

Chicago Metrowire Staff
••Healthcare
CK Life Sciences' Sequencio to Present Cancer Vaccine Data at SITC 2026, Advancing PINT Framework

CK Life Sciences Int'l., (Holdings) Inc. subsidiary Sequencio Therapeutics will present new preclinical data from its lead cancer vaccine programmes at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), the company announced via Media OutReach Newswire. The meeting takes place 4-8 November 2026 in Phoenix, Arizona, and two abstracts from Sequencio have been selected for poster presentation on 6 November.

The presentations are significant because they provide the first public look at data supporting Sequencio's Prime–Infiltrate–Ignite–Translate (PINT) translational research framework, which the company uses to guide development of its cancer vaccine candidates. Both studies address two central challenges in cancer immunotherapy: helping the immune system recognise and attack cancer cells, and overcoming mechanisms that tumours use to evade immune responses.

The first study evaluated CKLS118, a TROP2-targeted circular RNA vaccine, in combination with anti-PD-1 therapy in TROP2-positive tumour models. The combination significantly increased activated IFN-γ-positive CD4+ and CD8α+ T-cell subsets within tumours, indicating greater local immune activation. In the 4T1-hTROP2 model, tumour growth inhibition reached 74.7% and 88.9% when the vaccine was combined with 0.3 and 1.0 mg/kg anti-PD-1, respectively, compared with 28.9% and 68.6% with anti-PD-1 alone. These findings support further development of CKLS118 in combination with checkpoint inhibition and evaluation of a potential dose-sparing strategy.

The second study examined CKLS202, a dual-antigen vaccine co-targeting human PD-L1 and PRAME. In humanised models, vaccination induced robust PRAME-specific T-cell responses, anti-human PD-L1 antibody titres above 1:16,000 and functional hPD-1/hPD-L1 blockade. In an efficacy model, vaccination achieved 65% tumour growth inhibition and was associated with increased tumour-infiltrating CD4+ cells, more than twofold increases in interferon-γ and granzyme B, and a more than fivefold reduction in the M2 macrophage marker CD163, consistent with a shift towards a more immune-active tumour environment. Vaccinated tumour-free mice were also protected against tumour rechallenge, supporting durable antigen-specific immunity.

Dr Melvin Toh, Vice President and Chief Scientific Officer of CK Life Sciences, said the posters provide an important opportunity to share new data with the international immuno-oncology community. He added that the findings may help inform future clinical development in peri-operative settings, where lower tumour burden may give vaccine-induced immunity a greater opportunity to control residual disease.

The data matter because they offer preclinical validation of two complementary strategies that could eventually broaden treatment options for cancers expressing TROP2, PD-L1 or PRAME. By demonstrating meaningful tumour growth inhibition and, in the PD-L1/PRAME programme, durable immune protection, the results support continued advancement of both vaccine candidates toward human clinical trials. For CK Life Sciences, the presentations also signal a strategic push into next-generation therapeutic cancer vaccines, a field aiming to shift cancer treatment from transient tumour reduction toward sustained, immune-controlled remission.

Blockchain Registration

QR Code for Blockchain Registration